NewsBlazeIN – Lifestyle
Author:
ABBISKO THERAPEUTICS
AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches
April 23, 2026
Abbisko Therapeutics’ FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma
March 31, 2026
Abbisko Therapeutics’ FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children
March 31, 2026